Solana Company (HSDT) CMO resigns, receives $875,000 lump-sum payout
Rhea-AI Filing Summary
Solana Company announced that Antonella Favit‑Van Pelt, MD, PhD, has mutually agreed with the company to resign as Chief Medical Officer, effective April 8, 2026. The parties entered into a Separation Agreement effective the same date.
Under this agreement, Dr. Favit‑Van Pelt will receive a lump‑sum separation payment of $875,000, less applicable withholdings, to be paid within ten business days after the effective date. In return, she waives and releases employment‑related claims and must continue to honor confidentiality and invention assignment obligations from her employment agreement.
Positive
- None.
Negative
- Chief Medical Officer departure on April 8, 2026, creates leadership uncertainty in a critical clinical and regulatory role for Solana Company.
- $875,000 separation payment in a single lump sum represents a meaningful cash outlay tied to the executive’s exit.
Insights
Solana’s CMO exit brings leadership change and a sizable cash payout.
The departure of Chief Medical Officer Antonella Favit‑Van Pelt concentrates attention on Solana’s clinical and regulatory leadership. A CMO role is strategically important in healthcare, often overseeing clinical development, safety, and interactions with regulators and investigators.
The Separation Agreement grants a $875,000 lump‑sum payment within ten business days after April 8, 2026, in exchange for a waiver of employment‑related claims and continued confidentiality and invention obligations. Future disclosures in company filings may clarify succession plans for this key position and any resulting impact on clinical operations.
8-K Event Classification
Key Figures
Key Terms
Separation Agreement financial
Emerging growth company regulatory
Item 5.02 regulatory
Inline XBRL technical
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| ||
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 8, 2026, Solana Company (the “Company”) and Antonella Favit-Van Pelt, MD, PhD, mutually agreed that Dr. Favit-Van Pelt would separate from the Company and resign as the Company’s Chief Medical Officer, effective as of April 8, 2026 (the “Effective Date”). In connection with her separation from the Company, the Company and Dr. Favit-Van Pelt entered into a separation agreement, effective as of the Effective Date (the “Separation Agreement”).
Pursuant to the Separation Agreement, Dr. Favit-Van Pelt is entitled to a separation payment of $875,000, to be paid in a single lump sum payment, less applicable withholdings, to be made within ten business days after the Effective Date. In exchange for the consideration provided to Dr. Favit-Van Pelt pursuant to the Separation Agreement, Dr. Favit-Van Pelt agreed to waive and release any claims in connection with Dr. Favit-Van Pelt’s employment and separation from the Company. Dr. Favit-Van Pelt must also continue to comply with the confidential information and invention assignment provisions set forth in Dr. Favit-Van Pelt’s employment agreement with the Company.
The foregoing summary description of the terms of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the Separation Agreement, which is filed as Exhibit 10.1 hereto.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. | | Description |
10.1 | Separation Agreement, dated as of April 8, 2026, by and between Solana Company and Antonella Favit-Van Pelt. | |
104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SOLANA COMPANY. | ||
|
|
|
|
Dated: April 13, 2026 |
| By: | /s/ Jeffrey S. Mathiesen |
|
|
| Jeffrey S. Mathiesen |
|
|
| Chief Financial Officer, Treasurer and Secretary |
3